Rifaximin crystalline forms and methods of preparation thereof
The present invention is directed to methods for preparation of a composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β. For example, practice of a method of the invention can provide the composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β wherein the rifaximin β is present in about 3-12% (w/w) or is present in about 5-8% (w/w). The composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β is prepared by dissolving raw rifaximin in a water-soluble organic solvent, for example ethanol, at reflux, then adding water to achieve a final mixed solvent of about 7:3 (v/v) solvent to water ratio, then cooling to 35-40° C. until crystallization commences, then further cooling with stirring to 0° C., then recovery of the crystallized material, and drying to a water content of between 2.5% and 5.0%, to provide the composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β. The composition is suitable for medicinal use, such as in treatment of infections of the gastrointestinal tract.
1. A method for the manufacture of a composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β, comprising:
(a) dissolving rifaximin in a water-soluble organic solvent and warming the organic solvent to reflux; then, when the rifaximin is completely dissolved in the organic solvent to provide a solution of rifaximin in the organic solvent,
(b) adding water to the solution to provide a second solution of rifaximin in a mixed solvent, the mixed solvent having an organic solvent to water ratio of about 5:5 to about 9:1 (v/v), to provide the second solution of rifaximin in the mixed solvent; then,
(c) cooling the second solution to a temperature of 25-50° C., and stirring at the temperature of 25-50° C. until crystallization takes place, then
(d) cooling the solution to about 0° C. with stirring, then,
(e) recovering the crystallized material, then
(f) drying the crystallized material to a water content of between 2.5% and 5.0%;
to provide the composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β, wherein the composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β contains about 3% up to about 12% (w/w) of the rifaximin β crystalline polymorph in mixture with a remaining percentage of the rifaximin α crystalline polymorph.
2. The method of claim 1 , wherein the organic solvent to water ratio is about 7:3 (v/v).
3. The method of claim 1 , wherein cooling the second solution is to a temperature of 35-40° C., and stirring at the temperature of 35-40° C. continues until crystallization takes place.
4. The method of claim 1 , wherein the water-soluble organic solvent is an alcohol.
5. The method of claim 4 , wherein the alcohol is ethanol.
6. The method of claim 4 , wherein the alcohol is methanol, isopropanol, or n-propanol, or any mixture thereof.
7. The method of claim 1 , wherein the water-soluble organic solvent is a ketone.
8. The method of claim 7 , wherein the ketone is acetone.
9. The method of claim 1 , wherein the water-soluble organic solvent is a mixture of an alcohol and a ketone.
10. A rifaximin composition comprising mixed crystalline polymorphs rifaximin α and rifaximin β prepared by the method of claim 1 , containing about 3-13% (w/w) of the rifaximin β crystalline polymorph in mixture with a remaining percentage of the rifaximin α crystalline polymorph.
11. A method of treatment of a condition in a patient for which rifaximin is medically indicated, wherein the condition comprises a gastrointestinal (GI) infection and the composition is administered orally, comprising administration to the patient of an effective amount of a rifaximin composition prepared by the method of claim 1 or of a rifaximin composition of claim 10 .
12. A pharmaceutical composition for oral administration comprising an effective amount of a rifaximin composition prepared by the method of claim 1 , or of a rifaximin composition of claim 10 .